Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To determine final height gain, the researchers assessed the difference between the attained final height and the final height predictions at the start of treatment.

Who Took Part

PubMed indexes the participants as children and teenagers, women only.

These final height predictions were calculated using the Bayley-Pinneau (BP) prediction method, the modified projected adult height (mPAH), the modified index of potential height (mIPHRUS), and the Turner's specific prediction method (PTSRUS).

How the Study Was Run

The design is described as randomized and crossover.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

Nineteen girls with Turner's syndrome aged > or = 11 years (mean (SD) 13.6 (1.7) years).

What Was Measured

The subject headings attached to it are Body Height, Ethinyl Estradiol, Human Growth Hormone, Injections, Intradermal and Turner Syndrome.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1999 (Archives of disease in childhood), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.